CTLA4 and melanoma: This is illustrated by the particular effectiveness of both nivolumab, and pembrolizumab (targeting PD-1) and ipilimumab (targeting CTLA-4) against a subset of patients with Non-Small Cell Lung Cancer (NSCLCs) and melanoma.